Business
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site
U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering
About this update from Immix Biopharma, Inc.
[{"type":"text","content":" U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company’s existing CAR-T GMP manufacturing process to the United StatesCommencement of U.S. engineering batches follows selection of U.S. GMP manufacturer in February 2023 LOS ANGELES, May 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the commencement of CAR-T NXC-201 Engineering Batches at its U.S. Manufacturing Site. These U.S. engineering batches will support the planned U.S. expansion of the Company’s ongoing Phase 1b/2a NEXICART-1 (NCT04720313) study of its novel BCMA-targeted chimeric antigen receptor T (car-T) cell therapy NXC-201. This manufacturing milestone represents a crucial next step in transferring the Company’s existing CAR-T GMP manufacturing process to the United States following the selection of a U.S. GMP manufacturer in February 2023. “We are working tirelessly to bring NXC-201 to U.S. patients,” said Ilya Rachman, M.D. PhD Chief Executive Officer of Immix Biopharma. “NXC-201 is the first CAR-T being developed in AL Amyloidosis, and in Multiple Myeloma, patients face significant obstacles when seeking BCMA-targeted CAR-T treatments like NXC-201. We look forward to continuing to advance NXC-201 as we work to improve treatment outcomes for patients in the U.S. suffering from AL amyloidosis and multiple myeloma.” “Today, 95% of U.S. medical centers are unable to offer CAR-T cell therapy,” said Gabriel Morris, Chief Financial Officer of Immix Biopharma. “NXC-201 has already been trialed in over 50 patients, demonstrating a 1-2 day median short side-effect duration, which offers potential to become the first out-patient CAR-T, potentially reducing hospitalization costs up to 80% and enabling dosing in 95% of U.S. medical centers today unable to offer CAR-T cell therapy.” About NXC-201 NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis across 58 patients. About NEXICART-1 NEXICART-1 (NCT04720313) is an ongo...